JP2021513536A5 - - Google Patents

Info

Publication number
JP2021513536A5
JP2021513536A5 JP2020542822A JP2020542822A JP2021513536A5 JP 2021513536 A5 JP2021513536 A5 JP 2021513536A5 JP 2020542822 A JP2020542822 A JP 2020542822A JP 2020542822 A JP2020542822 A JP 2020542822A JP 2021513536 A5 JP2021513536 A5 JP 2021513536A5
Authority
JP
Japan
Prior art keywords
domain
composition according
linker
composition
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542822A
Other languages
English (en)
Japanese (ja)
Other versions
JP7279054B2 (ja
JP2021513536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/053136 external-priority patent/WO2019154986A1/en
Publication of JP2021513536A publication Critical patent/JP2021513536A/ja
Publication of JP2021513536A5 publication Critical patent/JP2021513536A5/ja
Priority to JP2023077703A priority Critical patent/JP2023113648A/ja
Application granted granted Critical
Publication of JP7279054B2 publication Critical patent/JP7279054B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542822A 2018-02-09 2019-02-08 Ｅｄｂ標的化ｉｌ－１２組成物 Active JP7279054B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023077703A JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18156141 2018-02-09
EP18156141.6 2018-02-09
EP18179313 2018-06-22
EP18179313.4 2018-06-22
PCT/EP2019/053136 WO2019154986A1 (en) 2018-02-09 2019-02-08 Edb targeting il-12 compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023077703A Division JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Publications (3)

Publication Number Publication Date
JP2021513536A JP2021513536A (ja) 2021-05-27
JP2021513536A5 true JP2021513536A5 (https=) 2022-01-31
JP7279054B2 JP7279054B2 (ja) 2023-05-22

Family

ID=65268973

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542822A Active JP7279054B2 (ja) 2018-02-09 2019-02-08 Ｅｄｂ標的化ｉｌ－１２組成物
JP2023077703A Pending JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023077703A Pending JP2023113648A (ja) 2018-02-09 2023-05-10 Ｅｄｂ標的化ｉｌ－１２組成物

Country Status (25)

Country Link
US (1) US12173044B2 (https=)
EP (1) EP3749372B1 (https=)
JP (2) JP7279054B2 (https=)
KR (2) KR102488801B1 (https=)
CN (1) CN111683687B (https=)
AU (2) AU2019219201B2 (https=)
BR (1) BR112020012888A2 (https=)
CA (1) CA3087488C (https=)
CL (1) CL2020002052A1 (https=)
CO (1) CO2020009737A2 (https=)
CR (1) CR20200342A (https=)
CU (1) CU20200054A7 (https=)
EC (1) ECSP20047171A (https=)
ES (1) ES3035714T3 (https=)
IL (1) IL275713A (https=)
JO (1) JOP20200193A1 (https=)
MX (1) MX2020008231A (https=)
MY (1) MY200700A (https=)
PE (1) PE20210122A1 (https=)
PH (1) PH12020551230A1 (https=)
RU (2) RU2758143C1 (https=)
SG (1) SG11202006334XA (https=)
TW (1) TWI844524B (https=)
UY (1) UY38074A (https=)
WO (1) WO2019154986A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
WO2021050789A1 (en) 2019-09-10 2021-03-18 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
AU2021257594B2 (en) * 2020-04-14 2024-02-15 Philogen S.P.A. Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain B of fibronectin
KR102649794B1 (ko) * 2020-10-19 2024-03-22 고려대학교 산학협력단 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법
JP7690131B2 (ja) * 2022-01-04 2025-06-09 フィロジェン ソチエタ ペル アツィオーニ Ｉｌ－１２を含むイムノサイトカインとキナーゼ阻害剤の組合せ
CN118359730A (zh) * 2023-01-17 2024-07-19 上海君赛生物科技有限公司 包含细胞因子的靶向型融合蛋白
WO2025061801A1 (en) 2023-09-19 2025-03-27 Philochem Ag Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate
WO2025251110A1 (en) * 2024-06-03 2025-12-11 Selvax Pty Ltd Anti-cd40 antibody il-2 fusion proteins
WO2026003203A1 (en) 2024-06-27 2026-01-02 Philogen S.P.A. Combination of an immunocytokine comprising targeted il2 and a jak inhibitor
WO2026013184A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Fusion protein peptide linkers and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994104A (en) * 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
JP2003524018A (ja) 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
AU2001239470A1 (en) * 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
EP2174958A1 (en) 2002-03-11 2010-04-14 Philogen S.p.A. Antibodies derived from anti ed-b l19 and targeting tumor vasculature
EP1702069A2 (en) * 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
CA2607954A1 (en) * 2005-05-11 2006-11-16 Philogen S.P.A. Conjugate for targeting of drug
CA2747154C (en) * 2008-12-19 2015-11-10 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
JP5764127B2 (ja) 2009-08-17 2015-08-12 ロシュ グリクアート アーゲー 標的化イムノコンジュゲート
ES2872964T3 (es) * 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
CA2910044A1 (en) * 2013-04-26 2014-10-30 Philogen S.P.A. Il4 conjugated to antibodies against extracellular matrix components
WO2017062953A1 (en) 2015-10-10 2017-04-13 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
CN110997718B (zh) * 2017-06-07 2023-11-10 菲洛根股份公司 血管内皮生长因子/抗纤连蛋白抗体融合蛋白
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物

Similar Documents

Publication Publication Date Title
JP2021513536A5 (https=)
RU2021130306A (ru) Композиции il-12, нацеленные на edb
JP2024526145A5 (https=)
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP2023507190A5 (https=)
RU2020114632A (ru) Терапевтические способы, относящиеся к ингибиторам hsp90
JP2019506403A5 (https=)
JP2016518387A5 (https=)
JP2016528162A5 (https=)
TW202214243A (zh) 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用
JP2017537927A5 (https=)
JP2023524789A5 (https=)
JP2024016209A5 (https=)
JP2008500277A5 (https=)
Razak et al. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: ARA Razak et al.
JP2020536048A5 (https=)
Vaisitti et al. Vls-101 is a novel therapeutic antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in Richter's syndrome (RS)
JP2023524359A5 (https=)
JP2024028756A5 (https=)
JP2018537433A5 (https=)
JP7357386B2 (ja) 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用
JP2015510945A5 (https=)
WO2025033367A1 (ja) 抗腫瘍剤併用療法
JP2025512950A5 (https=)
JP2021511352A5 (https=)